News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BioTie Therapies Corp. Updates Outlook: Intends To Develop SYN120 Internally And Will Not Exercise Its Option To Acquire Neurelis Until Further Notice


2/28/2014 9:54:49 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SYN120: Biotie has been in advanced discussions for a partnership for further development and commercialization of SYN120, its oral, dual antagonist of the 5- HT6 and 5HT2a receptors. These two distinct properties could result in a unique therapeutic profile for SYN120 combining pro-cognitive and antipsychotic activities. SYN120 has completed single and multiple ascending dose Phase 1 clinical studies and a Phase 1 positron emission tomography imaging study to determine therapeutic dose for subsequent Phase 2 studies. The Company has now concluded that Biotie will be better served by progressing SYN120 internally to the next stage of development. Preparations for a Phase 2 study in Alzheimer's disease have started, with the study expected to begin recruitment by the end of 2014.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES